Palisade Capital Management

mobile
news-insights-top
Home > News & Insight > Private Equity News

News & Insight



Private Equity News

Wednesday, September 24, 2014
PCEPII Portfolio Company Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis and Welcomes Charlie Stiefel and Bill Ju to Board of Directors
Posted in Private Equity News
Brickell Biotech, Inc. (“Brickell”), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative therapeutics to satisfy current unmet human needs in the global dermatology markets, today announced the outcome of a pilot study of a new compound, BBI-4000, for the topical treatment of primary axillary hyperhidrosis, or excessive sweating.
Sunday, July 20, 2014
PCEPII Portfolio Company Shoe Sensation Opening its 100th Store and Celebrating 30th Anniversary
Posted in Private Equity News
Shoe Sensation is taking rural communities by storm as it opens its 100th store this year and celebrates 30 years of bringing well-known footwear brands to small-town America. "We have been able to survive through the thick and thin of the economy and expand our model currently to 14 states – 16 states come September," CEO Mike Zawoysky says. “We have been able to deliver new stores each year and comparable store growth for each of the past six consecutive years."
Tuesday, July 01, 2014
Telerx Completes Acquisition of PPP Portfolio Company C3i to Enhance Pharmaceutical Solutions, Services and Global Capabilities
Posted in Private Equity News
Telerx, a leader in U.S. customer care services, today announced that it has completed its acquisition of C3i, a leading provider of technology support services for the life sciences industry. This acquisition will provide Telerx with the global infrastructure to expand its business services outside the United States while maintaining its current domestic operations. The acquisition was completed on June 30, 2014.
Monday, June 30, 2014
PCEPII Portfolio Company Brickell Biotech Announces Licensing Agreement for its Novel Retinoid Therapy with Merz North America
Posted in Private Equity News
Brickell Biotech, Inc. ("Brickell"), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative, therapeutics to satisfy current unmet human needs in the global dermatology markets, today announced that it has entered into a license agreement with Merz North America, Inc. ("Merz"). The agreement grants Merz an exclusive North American license, with certain additional international rights, to develop and commercialize a completely novel retinoid compound, BBI-3000, for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis.
Monday, April 28, 2014
PPPII Portfolio Company Promosome and GE Healthcare Life Sciences Sign Licensing Agreement
Posted in Private Equity News
GE Healthcare Life Sciences (NYSE: GE) and Promosome LLC announced today that the companies have signed a licensing agreement, granting GE Healthcare exclusive rights to an innovative suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture. Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.
Thursday, April 10, 2014
PCEPII Portfolio Company SEND WORD NOW® RECOGNIZED AS ‘LEADER’ IN GARTNER’S 2014 MAGIC QUADRANT FOR U.S. EMERGENCY/MASS NOTIFICATION SERVICES
Posted in Private Equity News
Send Word Now, leading worldwide provider of enterprise-class critical communications, has again been named as a ‘Leader’ in Gartner Inc.’s Magic Quadrant for U.S. Emergency/Mass Notification Services (EMNS). ‘Leaders,’ as defined by Gartner, "have products that work well for Gartner clients in midsize and large deployments. They excel in the combination of market understanding, product features and functions, and overall viability as a firm. Their EMNS products are well-known to clients, and are frequently found on RFP shortlists."
 < 1 2 3 > 
Latest Research and White Papers
Friday, July 10, 2020
The Time for Convertibles is Now
We believe convertible securities, which complement other alpha-seeking strategies within a portfolio, have always been an attractive asset class and should play a vital role in strategic allocations during these unprecedented times.
Find Out More and Request This White Paper

See all Research and White Papers



Select A Category

Connect with Us

One Bridge Plaza, Suite 695, Fort Lee, New Jersey 07024 | (201) 585-7733 | Get Directions | Contact Us

Stay Informed

Sign up for our mailing list and stay up to date on the latest information and news from Palisade Capital Management.